Research progress on the involvement of tumor microenvironment in mediating trastuzumab resistance in HER2-positive breast cancer

doi:10.3877/cma.j.issn.1674-3946.2024.01.024

Abstract

Abstract:

Trastuzumab is a monoclonal antibody targeting human epidermal growth factor receptor-2 (HER2), which can regulate the expression of HER2 and its downstream signaling function, regulate cell cycle, inhibit tyrosine kinase activity, slow down tumor angiogenesis and regulate tumor immune microenvironment. In HER2-positive breast cancer, trastuzumab is used as a first-line treatment throughout preoperative neoadjuvant therapy and postoperative targeted therapy. However, in recent years, as breast cancer has become the first most frequent tumor in women, the problem of trastuzumab resistance has become more and more common. Studies have shown that tumor microenvironment plays an important role in trastuzumab resistance, which can affect the development and prognosis of HER2-positive breast cancer. This review summarizes the progress of tumor microenvironment in the mechanism of trastuzumab resistance in recent years, emphasizes the role of NK cells, and Outlines the methods to overcome resistance and improve patient prognosis.

Key words: Human Epidermal Growth Factor Receptor-2, Trastuzumab, Drug Resistance, Tumor Microenvironment, ADCC

Changqing Cao, Xinyan Guo, Yuan Gao, Cun Zhang, Haili Tang, Dong Fan, Xiaojun Yang, Song Zhang, Huadong Zhao. Research progress on the involvement of tumor microenvironment in mediating trastuzumab resistance in HER2-positive breast cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 90-95.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2024.01.024

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2024/V18/I01/90

Figures/Tables 1

References 71

[1]	Siegel RL，Miller KD，Fuchs HE，et al. Cancer Statistics，2022[J]. CA Cancer J Clin, 2022, 72(1): 7–33.
[2]	崔志超,马杰,王雅琪等.HER2阳性乳腺癌患者新辅助化疗后免疫分型变化的研究[J/CD].中华普外科手术学杂志（电子版）, 2020, 14(02): 189–192.
[3]	Weng Y，Liang W，Ji Y，et al. Key Genes and Prognostic Analysis in Her2+ Breast Cancer[J]. Technol Cancer Res Treat, 2021, 20(1): 7–30.
[4]	Jerusalem G，Lancellotti P，KIM SB. Her2+ Breast Cancer Treatment and Cardiotoxicity: Monitoring and Management[J]. Breast Cancer Res Treat, 2019, 177(2): 237–250.
[5]	Zimmer AS，Van Swearingen A，Anders CK. Her2-Positive Breast Cancer Brain Metastasis: A New and Exciting Landscape[J]. Cancer Rep（Hoboken）, 2022, 5(4): e1274.
[6]	江泽飞,边莉.乳腺癌表皮生长因子受体-2分子靶向治疗临床应用策略[J/CD].中华普外科手术学杂志（电子版）, 2011, 5(04): 380–386.
[7]	Chumsri S，Sperinde J，Liu H，et al. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52（Alliance）[J]. Clin Cancer Res, 2018, 24(13): 3053–3058.
[8]	Mercogliano MF，De Martino M，Venturutti L，et al. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer[J]. Clin Cancer Res, 2017, 23(3): 636–648.
[9]	Lu Y，Zi X，Zhao Y，et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab（Herceptin）[J]. J Natl Cancer Inst, 2001, 93(24): 1852–1857.
[10]	Sudhan DR，Schwarz LJ，Guerrero-Zotano A，et al. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER（+）/HER2（+）Breast Cancers: Implications to the ExteNET Trial[J]. Clin Cancer Res, 2019, 25(2): 771–783.
[11]	Noorolyai S，Shajari N，Baghbani E，et al. The relation between PI3K/AKT signalling pathway and cancer[J]. Gene, 2019, 698: 120–128.
[12]	Baker J，Kyle AH，Reinsberg SA，et al. Heterogeneous Distribution of Trastuzumab in Her2-Positive Xenografts and Metastases: Role of the Tumor Microenvironment[J]. Clin Exp Metastasis, 2018, 35(7): 691–705.
[13]	Iwase T，Wang X，Shrimanker TV，et al. Body Composition and Breast Cancer Risk and Treatment: Mechanisms and Impact[J]. Breast Cancer Res Treat, 2021, 186(2): 273–283.
[14]	Kim DS，Scherer PE. Obesity，Diabetes，and Increased Cancer Progression[J]. Diabetes Metab J, 2021, 45(6): 799–812.
[15]	Ewertz M，Jensen M，Gunnarsdottir KA，et al. Effect of Obesity On Prognosis After Early-Stage Breast Cancer[J]. Journal of clinical oncology, 2011, 29(1): 25–31.
[16]	Duong MN，Cleret A，Matera E，et al. Adipose Cells Promote Resistance of Breast Cancer Cells to Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity[J]. Breast Cancer Research, 2015, 17(1): 57.
[17]	Rybinska I，Mangano N，Tagliabue E，et al. Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences[J]. Int J Mol Sci, 2021, 22(7): 3775.
[18]	Bochet L，Lehuédé C，Dauvillier S，et al. Adipocyte-Derived Fibroblasts Promote Tumor Progression and Contribute to the Desmoplastic Reaction in Breast Cancer[J]. Cancer Res, 2013, 73(18): 5657–5668.
[19]	Ren J，Smid M，Iaria J，et al. Cancer-Associated Fibroblast-Derived Gremlin 1 Promotes Breast Cancer Progression[J]. Breast Cancer Res, 2019, 21(1): 109.
[20]	Piersma B，Hayward MK，Weaver VM. Fibrosis and Cancer: A Strained Relationship[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188356.
[21]	Tsuyada A，Chow A，Wu J，et al. Ccl2 Mediates Cross-Talk Between Cancer Cells and Stromal Fibroblasts that Regulates Breast Cancer Stem Cells[J]. Cancer Res, 2012, 72(11): 2768–2779.
[22]	Chatterjee A，Jana S，Chatterjee S，et al. Microrna-222 Reprogrammed Cancer-Associated Fibroblasts Enhance Growth and Metastasis of Breast Cancer[J]. Br J Cancer, 2019, 121(8): 679–689.
[23]	Xu Y，Zhou X，Mei M，et al. Reprograming Carcinoma Associated Fibroblasts by Micrornas[J]. Curr Mol Med, 2017, 17(5): 341–349.
[24]	Shen H，Yu X，Yang F，et al. Reprogramming of Normal Fibroblasts Into Cancer-Associated Fibroblasts by Mirnas-Mediated Ccl2/Vegfa Signaling[J]. PLoS Genet, 2016, 12(8): e1006244.
[25]	Guardia C，Bianchini G，Arpí-Llucià O，et al. Preclinical and Clinical Characterization of Fibroblast-Derived Neuregulin-1 On Trastuzumab and Pertuzumab Activity in Her2-Positive Breast Cancer[J]. Clin Cancer Res, 2021, 27(18): 5096–5108.
[26]	Muntasell A，Cabo M，Servitja S，et al. Interplay Between Natural Killer Cells and Anti-Her2 Antibodies: Perspectives for Breast Cancer Immunotherapy[J]. Front Immunol, 2017, 8: 1544.
[27]	Feng M，Marjon KD，Zhu F，et al. Programmed Cell Removal by Calreticulin in Tissue Homeostasis and Cancer[J]. Nat Commun, 2018, 9(1): 3194.
[28]	Betancur PA，Abraham BJ，Yiu YY，et al. A Cd47-Associated Super-Enhancer Links Pro-Inflammatory Signalling to Cd47 Upregulation in Breast Cancer[J]. Nat Commun, 2017, 8: 14802.
[29]	Jaiswal S，Jamieson CH，Pang WW，et al. Cd47 is Upregulated On Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis[J]. Cell, 2009, 138(2): 271–285.
[30]	Upton R，Banuelos A，Feng D，et al. Combining Cd47 Blockade with Trastuzumab Eliminates Her2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance[J]. Proc Natl Acad Sci U S A, 2021, 118(29): e2026849118.
[31]	Hu X，Liu Y，Zhang X，et al. The Anti-B7-H4 Checkpoint Synergizes Trastuzumab Treatment to Promote Phagocytosis and Eradicate Breast Cancer[J]. Neoplasia, 2020, 22(11): 539–553.
[32]	Pan Y，Yu Y，Wang X，et al. Tumor-Associated Macrophages in Tumor Immunity[J]. Front Immunol, 2020, 11: 583084.
[33]	Munir MT，Kay MK，Kang MH，et al. Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth[J]. Int J Mol Sci, 2021, 22(12): 6526.
[34]	Honkanen TJ，Moilanen T，Karihtala P，et al. Prognostic and Predictive Role of Spatially Positioned Tumour Infiltrating Lymphocytes in Metastatic Her2 Positive Breast Cancer Treated with Trastuzumab[J]. Sci Rep, 2017, 7(1): 18027.
[35]	Andre F，Dieci MV，Dubsky P，et al. Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer[J]. Clin Cancer Res, 2013, 19(1): 28–33.
[36]	Vinay DS，Ryan EP，Pawelec G，et al. Immune Evasion in Cancer: Mechanistic Basis and Therapeutic Strategies[J]. Semin Cancer Biol, 2015, 35 Suppl: S185–S198.
[37]	Plitas G，Konopacki C，Wu K，et al. Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer[J]. Immunity, 2016, 45(5): 1122–1134.
[38]	Force J，Howie LJ，Abbott SE，et al. Early Stage Her2-Positive Breast Cancers Not Achieving a Pcr From Neoadjuvant Trastuzumab- Or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype[J]. Clin Breast Cancer, 2018, 18(5): 410–417.
[39]	Cao Y，Feng YH，Gao LW，et al. Artemisinin Enhances the Anti-Tumor Immune Response in 4T1 Breast Cancer Cells in Vitro and in Vivo[J]. Int Immunopharmacol, 2019, 70: 110–116.
[40]	Zhang J，Dunk CE，Shynlova O，et al. Tgfb1 Suppresses the Activation of Distinct Dnk Subpopulations in Preeclampsia[J]. EBioMedicine, 2019, 39: 531–539.
[41]	Mitsuiki N，Schwab C，Grimbacher B. What Did we Learn From Ctla-4 Insufficiency On the Human Immune System？[J]. Immunol Rev, 2019, 287(1): 33–49.
[42]	Zhang A，Ren Z，Tseng KF，et al. Dual Targeting of Ctla-4 and Cd47 On T（Reg）Cells Promotes Immunity Against Solid Tumors[J]. Sci Transl Med, 2021, 13(605): eabg8693.
[43]	Crinier A，Milpied P，Escalière B，et al. High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved Nk Cell Subsets in Humans and Mice[J]. Immunity, 2018, 49(5): 971–986.
[44]	Vivier E，Tomasello E，Baratin M，et al. Functions of Natural Killer Cells[J]. Nat Immunol, 2008, 9(5): 503–510.
[45]	Chiossone L，Dumas PY，Vienne M，et al. Natural Killer Cells and Other Innate Lymphoid Cells in Cancer[J]. Nat Rev Immunol, 2018, 18(11): 671–688.
[46]	Muntasell A，Rojo F，Servitja S，et al. Nk Cell Infiltrates and Hla Class I Expression in Primary Her2（+）Breast Cancer Predict and Uncouple Pathological Response and Disease-Free Survival[J]. Clin Cancer Res, 2019, 25(5): 1535–1545.
[47]	Terrén I，Orrantia A，Vitallé J，et al. Nk Cell Metabolism and Tumor Microenvironment[J]. Front Immunol, 2019, 10: 2278.
[48]	Kute TE，Savage L，Stehle JJ，et al. Breast Tumor Cells Isolated From in Vitro Resistance to Trastuzumab Remain Sensitive to Trastuzumab Anti-Tumor Effects in Vivo and to Adcc Killing[J]. Cancer Immunol Immunother, 2009, 58(11): 1887–1896.
[49]	Hsu J，Hodgins JJ，Marathe M，et al. Contribution of Nk Cells to Immunotherapy Mediated by Pd-1/Pd-L1 Blockade[J]. J Clin Invest, 2018, 128(10): 4654–4668.
[50]	Fuertes MB，Domaica CI，Zwirner NW. Leveraging Nkg2D Ligands in Immuno-Oncology[J]. Front Immunol, 2021, 12: 713158.
[51]	Basher F，Dhar P，Wang X，et al. Antibody Targeting Tumor-Derived Soluble Nkg2D Ligand Smic Reprograms Nk Cell Homeostatic Survival and Function and Enhances Melanoma Response to Pdl1 Blockade Therapy[J]. J Hematol Oncol, 2020, 13(1): 74.
[52]	Lazarova M，Steinle A. Impairment of Nkg2D-Mediated Tumor Immunity by Tgf-Β[J]. Front Immunol, 2019, 10: 2689.
[53]	Jun E，Song AY，Choi JW，et al. Progressive Impairment of Nk Cell Cytotoxic Degranulation is Associated with Tgf-Β1 Deregulation and Disease Progression in Pancreatic Cancer[J]. Front Immunol, 2019, 10: 1354.
[54]	Yang C，Qian C，Zhang T，et al. The Killing Effect of Tanshinol On Breast Cancer Cells: Insight Into the Reversion of Tgf-Β1-Mediated Suppression of Nk Cell Functions[J]. Front Biosci（Landmark Ed）, 2021, 26(11): 1106–1118.
[55]	Zheng G，Guo Z，Li W，et al. Interaction Between Hla-G and Nk Cell Receptor Kir2Dl4 Orchestrates Her2-Positive Breast Cancer Resistance to Trastuzumab[J]. Signal Transduct Target Ther, 2021, 6(1): 236.
[56]	Lee CM，Tannock IF. The Distribution of the Therapeutic Monoclonal Antibodies Cetuximab and Trastuzumab within Solid Tumors[J]. BMC Cancer, 2010, 10: 255.
[57]	Syed AK，Woodall R，Whisenant JG，et al. Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in Her2+ Breast Cancer[J]. Neoplasia, 2019, 21(1): 17–29.
[58]	Indira CV，Månsson AS，Barbachowska M，et al. Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine（T-Dm1）Cytotoxicity through Redistribution of Phosphorylated Caveolin-1[J]. Mol Cancer Res, 2020, 18(4): 644–656.
[59]	Noguchi M，Hirata N，Tanaka T，et al. Autophagy as a Modulator of Cell Death Machinery[J]. Cell Death Dis, 2020, 11(7): 517.
[60]	Abada A，Elazar Z. Getting Ready for Building: Signaling and Autophagosome Biogenesis[J]. EMBO Rep, 2014, 15(8): 839–852.
[61]	Janser FA，Tschan MP，Langer R. The Role of Autophagy in Her2-Targeted Therapy[J]. Swiss Med Wkly, 2019, 149: w20138.
[62]	Vega-Rubín-De-Celis S，Zou Z，Fernández ÁF，et al. Increased Autophagy Blocks Her2-Mediated Breast Tumorigenesis[J]. Proc Natl Acad Sci USA, 2018, 115(16): 4176–4181.
[63]	Zhao Y，Liu H，Liu Z，et al. Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism[J]. Cancer Res, 2011, 71(13): 4585–4597.
[64]	Kwapisz D. Pembrolizumab and Atezolizumab in Triple-Negative Breast Cancer[J]. Cancer Immunol Immunother, 2021, 70(3): 607–617.
[65]	Matusz-Fisher A，Tan AR. Combination of Her2-Targeted Agents with Immune Checkpoint Inhibitors in the Treatment of Her2-Positive Breast Cancer[J]. Expert Opin Biol Ther, 2022, 22(3): 385–395.
[66]	Tinker AV，Hirte HW，Provencher D，et al. Dose-Ranging and Cohort-Expansion Study of Monalizumab（Iph2201）in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group（Cctg）: Ind221[J]. Clin Cancer Res, 2019, 25(20): 6052–6060.
[67]	Lee SC，Shimasaki N，Lim J，et al. Phase I Trial of Expanded，Activated Autologous Nk-Cell Infusions with Trastuzumab in Patients with Her2-Positive Cancers[J]. Clin Cancer Res, 2020, 26(17): 4494–4502.
[68]	Granzin M，Wagner J，Köhl U，et al. Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation[J]. Front Immunol, 2017, 8: 458.
[69]	Lupo KB，Matosevic S. Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy[J]. Cancers（Basel）, 2019, 11(6): 769.
[70]	Portillo AL，Hogg R，Poznanski SM，et al. Expanded Human Nk Cells Armed with Car Uncouple Potent Anti-Tumor Activity From Off-Tumor Toxicity Against Solid Tumors[J]. iScience, 2021, 24(6): 102619.
[71]	Guillerey C，Huntington ND，Smyth MJ. Targeting Natural Killer Cells in Cancer Immunotherapy[J]. Nat Immunol, 2016, 17(9): 1025–1036.

Please choose a citation manager

Content to export